Clinical trial
Retinoblastoma Biomarker Study
NCT00342797 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00342797 |
|---|---|
| Title | Retinoblastoma Biomarker Study |
| Official title | Retinoblastoma Biomarker Study |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Study type | Observational |
| Conditions | Retinoblastoma, Melanoma, Sarcoma |
| Enrollment | 2,136 |
| Start date | Nov 17, 1993 |
| Primary completion | Mar 6, 2024 |
| Completion | Mar 6, 2024 |
| First posted | Jun 21, 2006 |
| Last update posted | Mar 7, 2024 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: